News
Context Therapeutics Announces IND Clearance for ONA-XR in Recurrent Endometrial Cancer
Context Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ONA-XR for the treatment of patients with progesterone receptor positive (PR+) ovarian cancer.
Context CEO Martin Lehr Named Finalist for EY Young Entrepreneur of The Year® in Greater Philadelphia
Context Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ONA-XR for the treatment of patients with progesterone receptor positive (PR+) ovarian cancer.
Context Therapeutics Receives FDA Fast Track Designation for ONA-XR for PR+ Ovarian Cancer
Context Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ONA-XR for the treatment of patients with progesterone receptor positive (PR+) ovarian cancer.